Treatment of cancers and hematopoietic stem cell disorders privileged by cxcl12-cxcr4 interaction
AssigneeCantex Pharmaceuticals, Inc.
InventorStephen Marcus
Life of this patent
Estimating the term…
Abstract
Methods are presented for treating cancers and hematopoietic stem cell disorders, comprising administering to a subject with a cancer or hematopoietic stem cell disorder who is receiving a treatment regimen, a heparin derivative capable of inhibiting, reducing, abrogating or otherwise interfering with the binding of CXCL12 to CXCR4, wherein the cancer or hematopoietic stem cell disorder is one in which interaction of CXCL12 with CXCR4 privileges the cancer or disordered HSCs against therapeutic intervention. In preferred embodiments, the heparin derivative is a substantially 2-O, 3-O-desulfated heparin derivative.
Claims48
A method of treating cancer, comprising:
- adjunctively administering to a patient receiving an antineoplastic treatment regimen a CXCL12-interacting heparinoid, in an amount and at a time effective to enhance effectiveness of the antineoplastic treatment regimen, wherein the cancer being treated is one in which interaction of CXCL12 with CXCR4 privileges the cancer against therapeutic intervention.
(canceled)
7-8. (canceled)
(canceled)
(canceled)
16-18. (canceled)
21-28. (canceled)
(canceled)
33-34. (canceled)
36-44. (canceled)
(canceled)
49-51. (canceled)
(canceled)
56-73. (canceled)
75-85. (canceled)
(canceled)
91-98. (canceled)
A method of treating a hematopoietic stem cell disorder, comprising:
- adjunctively administering to a subject with a hematopoietic stem cell disorder who is receiving a hypomethylating agent, a CXCL12-interacting heparinoid, in an amount and at a time effective to enhance effectiveness of the treatment regimen.
(canceled)
103-104. (canceled)
Dependencies are inferred from the claim text.